[go: up one dir, main page]

BR9713366A - Análogos de heptapeptìdeo oxitocina - Google Patents

Análogos de heptapeptìdeo oxitocina

Info

Publication number
BR9713366A
BR9713366A BR9713366-3A BR9713366A BR9713366A BR 9713366 A BR9713366 A BR 9713366A BR 9713366 A BR9713366 A BR 9713366A BR 9713366 A BR9713366 A BR 9713366A
Authority
BR
Brazil
Prior art keywords
analogs
oxytocin
synthesis
amino acid
heptapeptide
Prior art date
Application number
BR9713366-3A
Other languages
English (en)
Other versions
BR9713366B1 (pt
Inventor
Per Merlin
Anders Nilsson
Jerzy Trojnar
Carl-Johan Aurell
Pierre Riviere
Robert Haigh
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring Bv filed Critical Ferring Bv
Publication of BR9713366A publication Critical patent/BR9713366A/pt
Publication of BR9713366B1 publication Critical patent/BR9713366B1/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/16Oxytocins; Vasopressins; Related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06Antiabortive agents; Labour repressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18Feminine contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/10Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02Linear peptides containing at least one abnormal peptide link
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

"ANáLOGOS DE HEPTAPEPTìDEO OXITOCINA". Trata-se de análogos heptapeptídeos ou seus sais farmaceuticamente aceitáveis, que consistem em uma metade hexapeptídeo S e um resíduo beta-amino álcool terminal -C Z ligados à metade S por uma ligação amida, onde o beta-amino álcool Z é -NR-CH (Q) - CH~ 2~OH, Q é (CH~ 2~) -NH-A, n é 1-6 e A é H ou C-(=NH)NH~ 2~, é R é CH~ 3~ ou C~ 2~H~ 5~, e a metade S onde X é um alfa-aminoácido D-aromático e Y é um alfa-aminoácido alifático, e têm atividade antagonista oxitocina. Um processo de sua síntese; composições farmacêuticas contendo estes análogos; a síntese de tais composições; eum processo de controle de contrações uterinas, também são descritos.
BRPI9713366-3A 1996-11-26 1997-11-21 análogos de heptapeptìdeo oxitocina. BR9713366B1 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9604341A SE9604341D0 (sv) 1996-11-26 1996-11-26 Hepta-peptide oxytocin analogue
PCT/SE1997/001968 WO1998023636A1 (en) 1996-11-26 1997-11-21 Heptapeptide oxytocin analogues

Publications (2)

Publication Number Publication Date
BR9713366A true BR9713366A (pt) 2000-01-25
BR9713366B1 BR9713366B1 (pt) 2010-05-18

Family

ID=20404757

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI9713366-3A BR9713366B1 (pt) 1996-11-26 1997-11-21 análogos de heptapeptìdeo oxitocina.

Country Status (34)

Country Link
US (1) US6143722A (pt)
EP (1) EP0938496B1 (pt)
JP (1) JP3405460B2 (pt)
KR (1) KR100463132B1 (pt)
CN (1) CN1129606C (pt)
AR (1) AR008531A1 (pt)
AT (1) ATE242264T1 (pt)
AU (1) AU713424B2 (pt)
BR (1) BR9713366B1 (pt)
CA (1) CA2272990C (pt)
CZ (1) CZ299532B6 (pt)
DE (1) DE69722651T2 (pt)
DK (1) DK0938496T3 (pt)
EE (1) EE03832B1 (pt)
ES (1) ES2203823T3 (pt)
HR (1) HRP970630B1 (pt)
HU (1) HU228568B1 (pt)
IL (1) IL129519A (pt)
LT (1) LT4650B (pt)
LV (1) LV12350B (pt)
MY (1) MY125555A (pt)
NO (1) NO321380B1 (pt)
NZ (1) NZ336445A (pt)
PL (1) PL189292B1 (pt)
PT (1) PT938496E (pt)
RO (1) RO120772B1 (pt)
RU (1) RU2180668C2 (pt)
SE (1) SE9604341D0 (pt)
SI (1) SI20026B (pt)
SK (1) SK283800B6 (pt)
TR (1) TR199901028T2 (pt)
UA (1) UA54459C2 (pt)
WO (1) WO1998023636A1 (pt)
ZA (1) ZA9710518B (pt)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2181297C2 (ru) * 2000-06-20 2002-04-20 Эпштейн Олег Ильич Способ лечения патологического синдрома и лекарственное средство
US6476072B1 (en) * 2000-11-21 2002-11-05 Arthur Vanmoor Method of treating menstrual pain by enhancing the effectiveness of the human immune system
ATE346084T1 (de) * 2002-02-27 2006-12-15 Ferring Bv Zwischenprodukte und verfahren zur herstellung von heptapeptid-oxytocinanaloga
EP1504268A2 (en) * 2002-05-02 2005-02-09 Bayer HealthCare AG Diagnostics and therapeutics for diseases associated with oxytocin receptor (oxtr)
GB0210397D0 (en) * 2002-05-07 2002-06-12 Ferring Bv Pharmaceutical formulations
UA76639C2 (uk) * 2002-08-02 2006-08-15 Олєг Ільіч Епштєйн Гомеопатичний лікарський засіб та спосіб лікування еректильних дисфункцій
DK1500390T3 (da) * 2003-07-25 2005-09-19 Ferring Bv Farmaceutisk præparat som fast dosisform og fremgangsmåde til fremstilling deraf
PT1530967E (pt) * 2003-11-13 2006-09-29 Ferring Bv Embalagem blister e uma forma de dosagem solida que compreende desmopressina.
EP1555029A1 (en) 2004-01-19 2005-07-20 Ferring B.V. Use of substances having oxytocin antagonistic properties for the preparation of a medicament for treating hypertension
US20060171909A1 (en) * 2005-02-03 2006-08-03 The Procter & Gamble Company Cosmetic compositions comprising colorants with low free dye
SE0600482L (sv) * 2006-03-02 2006-11-14 Ferring Int Ct Sa Farmaceutisk sammansättning innefattande desmopressin, kiseldioxid och stärkelse
RU2472539C2 (ru) 2007-08-06 2013-01-20 Аллерган, Инк. Способы и устройства для доставки препарата десмопрессина
NZ587817A (en) * 2008-03-31 2012-05-25 Ferring Bv Oxytocin analogues
US20100286045A1 (en) 2008-05-21 2010-11-11 Bjarke Mirner Klein Methods comprising desmopressin
ES2710454T3 (es) 2008-05-21 2019-04-25 Ferring Bv Desmopresina bucodispersable para aumentar el periodo inicial de sueño ininterrumpido por nocturia
US11963995B2 (en) 2008-05-21 2024-04-23 Ferring B.V. Methods comprising desmopressin
TWI463990B (zh) * 2009-09-21 2014-12-11 Ferring Bv 催產素受體促進劑
GB2495884B (en) 2010-07-15 2017-05-31 Iliich Epshtein Oleg A method of increasing the effect of an activated-potentiated form of an antibody
JO3400B1 (ar) * 2010-09-30 2019-10-20 Ferring Bv مركب صيدلاني من كاربيتوسين
US9376467B2 (en) 2011-03-09 2016-06-28 Jitsubo Co., Ltd. Cross-linked peptides containing non-peptide cross-linked structure, method for synthesizing cross-linked peptides, and novel organic compound used in method
CN102875650B (zh) * 2012-09-26 2014-06-11 深圳翰宇药业股份有限公司 巴卢西班的制备方法
US9365615B2 (en) 2013-09-09 2016-06-14 Jitsubo Co., Ltd. Cross-linked peptides containing non-peptide cross-linked structure, method for synthesizing cross-linked peptides, and novel organic compound used in method
EP3037101B1 (en) 2014-12-22 2019-03-06 Ferring B.V. Oxytocin receptor antagonist therapy in the luteal phase for implantation and pregnancy in women undergoing assisted reproductive technologies
US9744209B2 (en) 2015-01-30 2017-08-29 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9750785B2 (en) 2015-01-30 2017-09-05 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9375478B1 (en) 2015-01-30 2016-06-28 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9925233B2 (en) 2015-01-30 2018-03-27 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9687526B2 (en) 2015-01-30 2017-06-27 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9937223B2 (en) 2015-01-30 2018-04-10 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
WO2017060339A1 (en) 2015-10-06 2017-04-13 Ferring B.V. New methods for making barusiban and its intermediates
PT3397622T (pt) 2016-01-04 2022-06-15 ObsEva SA Co-administração de alfa-amino éster de derivado de hidroxipropiltiazolidina e carboxamida e um agente tocolítico
JP7036791B2 (ja) 2016-07-21 2022-03-15 オブセヴァ エス.エー. 胚着床を促進し、流産を防ぐためのオキシトシンアンタゴニスト投与レジメン
JP7584201B2 (ja) 2019-09-03 2024-11-15 オブセヴァ エス.エー. 薬学的組成物
WO2021160597A1 (en) 2020-02-10 2021-08-19 ObsEva S.A. Biomarkers for oxytocin receptor antagonist therapy

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT89279B (pt) * 1987-12-21 1993-08-31 Sandoz Sa Processo para a preparacao de uma nova forma cristalina de ciclosporinas e de composicoes farmaceuticas que as contem
US5373089A (en) * 1988-09-02 1994-12-13 Northwestern University Oxytocin antagonist
CA2036973A1 (en) * 1990-02-27 1991-08-28 Mark G. Bock Cyclic hexapeptide oxytocin antagonists
SE9002384D0 (sv) * 1990-07-09 1990-07-09 Ferring Ab Derivat av baklobshormoner
DE4022247A1 (de) * 1990-07-12 1992-01-16 Hoechst Ag Verfahren zur extraktiven abtrennung von 2-alkylthio-5-phenylpyrimidinen aus ihren reaktionsgemischen
SE501678C2 (sv) * 1993-07-13 1995-04-10 Ferring Bv Peptid med oxytocinantagonistaktivitet samt farmaceutisk komposition innehållande nämnda peptid
SE523819C2 (sv) 1994-01-27 2004-05-18 Per-Ingvar Nilsson Accelerationsmunstycke samt metod för dess användning
SE9400918L (sv) 1994-03-18 1995-09-19 Anne Fjellstad Paulsen Stabiliserad komposition för oral administrering av peptider
SE503085C2 (sv) 1995-01-25 1996-03-25 Valeo Engine Cooling Ab Värmeväxlartank med ändstycken, förfarande för framställning av en sådan tank, samt värmeväxlare försedd med en sådan

Also Published As

Publication number Publication date
NO992532L (no) 1999-05-26
CA2272990C (en) 2002-11-19
MY125555A (en) 2006-08-30
ZA9710518B (en) 1998-06-10
HUP0000577A2 (hu) 2000-11-28
US6143722A (en) 2000-11-07
RO120772B1 (ro) 2006-07-28
JP3405460B2 (ja) 2003-05-12
KR20000069045A (ko) 2000-11-25
EP0938496A1 (en) 1999-09-01
IL129519A0 (en) 2000-02-29
DK0938496T3 (da) 2003-10-06
CN1129606C (zh) 2003-12-03
AU713424B2 (en) 1999-12-02
EE03832B1 (et) 2002-08-15
CN1238781A (zh) 1999-12-15
KR100463132B1 (ko) 2004-12-23
UA54459C2 (uk) 2003-03-17
EE9900210A (et) 1999-12-15
SI20026A (sl) 2000-02-29
NO992532D0 (no) 1999-05-26
EP0938496B1 (en) 2003-06-04
SI20026B (sl) 2000-06-30
NZ336445A (en) 2000-06-23
PL189292B1 (pl) 2005-07-29
BR9713366B1 (pt) 2010-05-18
LV12350A (lv) 1999-09-20
DE69722651T2 (de) 2004-04-08
HK1022481A1 (en) 2000-08-11
LT99052A (en) 2000-01-25
TR199901028T2 (xx) 1999-07-21
SE9604341D0 (sv) 1996-11-26
HRP970630B1 (en) 2002-04-30
SK70499A3 (en) 2000-10-09
ES2203823T3 (es) 2004-04-16
HUP0000577A3 (en) 2001-02-28
PT938496E (pt) 2003-10-31
LT4650B (lt) 2000-04-25
HU228568B1 (en) 2013-04-29
LV12350B (en) 1999-11-20
CZ183299A3 (cs) 2000-05-17
AU5142998A (en) 1998-06-22
NO321380B1 (no) 2006-05-02
DE69722651D1 (en) 2003-07-10
RU2180668C2 (ru) 2002-03-20
IL129519A (en) 2004-09-27
HRP970630A2 (en) 1998-10-31
WO1998023636A1 (en) 1998-06-04
SK283800B6 (sk) 2004-02-03
AR008531A1 (es) 2000-01-19
CA2272990A1 (en) 1998-06-04
ATE242264T1 (de) 2003-06-15
CZ299532B6 (cs) 2008-08-27
JP2000507617A (ja) 2000-06-20

Similar Documents

Publication Publication Date Title
BR9713366A (pt) Análogos de heptapeptìdeo oxitocina
MX9801716A (es) Derivados de meta-guanidina, urea, tiourea o acido aminobenzoico azaciclico, como antagonistas de integrina.
MY137301A (en) Peptide analogs as irreversible interleukin-1b protease inhibitors
NO952744L (no) Cytokinbegrensende midler
NO941611D0 (no) Nye aminosyrederivater, fremgangsmåte for deres fremstilling og farmasöytiske preparater inneholdende disse forbindelser
CA2200192A1 (en) Amidino and Guanidino Substituted Inhibitors of Trypsin-Like Enzymes
YU104592A (sh) Novi peptidni derivati
HUP0100669A2 (hu) Szerin proteázokat gátló peptidszármazékok és alkalmazásuk, valamint e vegyületeket tartalmazó gyógyászati készítmények
ATE99698T1 (de) Peptide.
FR2591485B1 (fr) Compositions stabilisees contenant l'activateur du plasminogene du tissu humain.
HU9302138D0 (en) Phenyl-imidazoline derivatives, pharmaceutical preparatives containing them as active substance and methods for producing said compounds and preparatives
ZA862776B (en) Substituted n-((4-piperidinyl)alkyl)bicyclic condensed oxazol-and thiazolamines
DK164326C (da) 6,6-ethylen-15,16-methylen-3-oxo-17alfa-pregn-4-en-21,17-carbolactoner, fremgangsmaade til deres fremstilling og farmaceutiske praeparater indeholdende dem
ES2012720A6 (es) Procedimiento para la obtencion de sales de adicion de acido de taurina o glicina amidada.
ES2001863A6 (es) Procedimiento para la fabricacion de derivados aminoalcoholes peptidicos que contienen un atomo de carbono tetrasubstituido, inhibidores de la renina y de las proteasas acidas
HUT53664A (en) Process for producing enzyme inhibiting amino acid derivatives and pharmaceutical compositions comprising such compounds as active ingredient
ES8601915A1 (es) Un procedimiento para preparar derivados de piridazinona
MC2254A1 (fr) Derives de la vasotocine
DE3666223D1 (en) Anticonvulsant agents
ATE46347T1 (de) Immunostimulierende peptide.
DE3476666D1 (en) Novel peptide, process for the preparation thereof and pharmaceutical composition containing said peptide
CA2123890A1 (en) Novel Sulfonic Acid Derivative and Medicinal Use Thereof
DE3855751D1 (en) Hypoglycemische peptide

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08G Application fees: restoration [chapter 8.7 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 18/05/2010, OBSERVADAS AS CONDICOES LEGAIS.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE AS 16A, 17A E 18A ANUIDADES.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.